Cell Therapy

CAMP4 Therapeutics closes $100m round to advance lead regRNA programmes

Biotechnology company CAMP4 Therapeutics has closed a $100m Series B round to progress its lead regRNA programmes and speed up the expansion of its regRNA Actuating Platform.

Castle Creek Biosciences raises $112.8m to progress gene therapies

Castle Creek Biosciences, a US-based late-stage cell and gene therapy company, has raised $112.8m to progress new gene therapies and expand pipeline.

ViGeneron signs gene therapy collaboration agreement with Regeneron Pharmaceuticals

ViGeneron, a Germany-based gene therapy company, has entered a target-specific strategic collaboration and option agreement with Regeneron Pharmaceuticals.

Charles River to acquire Vigene Biosciences for $292.5m

Charles River Laboratories International has agreed to buy Vigene Biosciences, a contract development and manufacturing organisation (CDMO) focused on gene therapies, for about $292.5m in cash.

Lilly, Biolojic to develop antibody therapies for diabetes treatment

Eli Lilly and Company has signed a research collaboration and license agreement with Biolojic Design to discover and develop therapies for diabetes treatment.

Lilly to provide antibody therapies at Indiana hospitals for treating COVID-19

Eli Lilly and Company (Lilly) has joined hands with local health systems in the US state of Indiana to provide antibody therapies through dedicated infusion centre locations that will offer treatments for patients with COVID-19.

GE researchers begin in-depth study to understand Covid-19 impact on lungs

Bioscience researchers at GE Research have begun an in-depth study to better understand the impact of the Covid-19 virus on the lungs.

Akron Biotech to exclusively manufacture Human AB Serum for Octapharma

Akron Biotechnology (Akron Biotech) has signed an exclusive global agreement with Swiss-based Octapharma, to manufacture virally inactivated Human AB Serum for the cell therapy market.

Cure Genetics, Boehringer to develop AAV vectors for gene therapy

Chinese biotechnology firm Cure Genetics has partnered with Boehringer Ingelheim for the development of novel Adeno-Associated Virus (AAV) vectors to be used in gene therapies.